10x Genomics (NASDAQ:TXG) Stock Price Expected to Rise, Piper Sandler Analyst Says

10x Genomics (NASDAQ:TXG) had its price objective hoisted by investment analysts at Piper Sandler from $15.00 to $19.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Piper Sandler’s target price suggests a potential upside of 13.84% from the company’s previous close.

A number of other analysts also recently commented on the company. Barclays boosted their price objective on 10x Genomics from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Zacks Research upgraded shares of 10x Genomics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. UBS Group upped their price target on shares of 10x Genomics from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Morgan Stanley lowered their price objective on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 12th. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the stock a “hold” rating in a report on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, 10x Genomics presently has a consensus rating of “Hold” and a consensus price target of $14.88.

10x Genomics Stock Up 0.6%

Shares of NASDAQ TXG opened at $16.69 on Tuesday. The stock has a market cap of $2.08 billion, a P/E ratio of -26.92 and a beta of 2.13. The firm’s 50-day simple moving average is $13.00 and its 200 day simple moving average is $11.95. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $17.70.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The company had revenue of $149.00 million for the quarter, compared to the consensus estimate of $142.50 million. During the same period in the previous year, the firm earned ($0.30) EPS. 10x Genomics’s revenue was down 1.7% on a year-over-year basis. 10x Genomics has set its Q4 2025 guidance at EPS. On average, sell-side analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Benjamin J. Hindson sold 7,486 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the transaction, the insider directly owned 440,888 shares of the company’s stock, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Serge Saxonov sold 9,348 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the transaction, the chief executive officer owned 945,892 shares in the company, valued at approximately $13,043,850.68. This represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 39,149 shares of company stock worth $539,865 over the last quarter. Corporate insiders own 9.39% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its holdings in shares of 10x Genomics by 420.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 755,380 shares of the company’s stock worth $8,829,000 after buying an additional 610,124 shares during the period. Cresset Asset Management LLC lifted its position in shares of 10x Genomics by 129.6% during the 3rd quarter. Cresset Asset Management LLC now owns 77,090 shares of the company’s stock worth $901,000 after purchasing an additional 43,516 shares during the last quarter. Level Four Advisory Services LLC bought a new stake in 10x Genomics during the 3rd quarter valued at approximately $640,000. 111 Capital acquired a new stake in shares of 10x Genomics in the third quarter worth $140,000. Finally, Choreo LLC grew its position in 10x Genomics by 73.8% in the 3rd quarter. Choreo LLC now owns 23,045 shares of the company’s stock worth $269,000 after purchasing an additional 9,782 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.